Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange
(Thomson Reuters ONE) -
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals
Limited (ASX.TLX) ("Telix", the "Company"), an Australian biopharmaceutical
company focused on the development of diagnostic and therapeutic products based
on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), has
today listed on the Australian Securities Exchange (ASX) after raising $50
million in a fully underwritten Initial Public Offering (IPO).
Telix's issue price is $65c per share, with a market capitalization of $128
million, placing the IPO as the largest for the Australian ASX biotechnology
sector, by capital raised, since 1994. The IPO was fully underwritten by the
Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited.
The IPO has been strongly supported by existing shareholders, which includes
both industry partners and domestic institutional investors such as Acorn
Capital, CVC, Monash Investors, Viburnum Funds, Alium Capital Management and
Allan Moss. Fidelity International is a cornerstone investor in the IPO at
approximately 10% of the issued capital of the Company.
Telix Co-Founder and CEO Dr. Christian Behrenbruch, "We are delighted with the
strong support from our partners, institutional and retail investors to make the
IPO success We believe this is a very exciting opportunity for investors and we
look forward to keeping shareholders closely informed of our progress as we
develop our oncology product pipeline and engage with commercial partners."
Proceeds from the IPO will fund the development and completion of clinical
trials for Telix's pipeline in renal (kidney), prostate and brain cancer
(glioblastoma), and enable the Company to complete multiple clinical and product
development milestones over the next 24 months.
Corporate Contact
Dr Christian Behrenbruch
CEO
Telix Pharmaceuticals Limited
Email: chris(at)telixpharma.com
Investor and Media Relations
Kyahn Williamson
WE Buchan
Tel: +61 (3) 9866 4722
Email: kwilliamson(at)buchanwe.com.au
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Telix Pharmaceuticals Limited via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 15.11.2017 - 02:00 Uhr
Sprache: Deutsch
News-ID 568190
Anzahl Zeichen: 2708
contact information:
Town:
North Melbourne
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 268 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange"
steht unter der journalistisch-redaktionellen Verantwortung von
Telix Pharmaceuticals Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
